Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
The vaccine will be administered to girls between the ages of nine and 16 as part of the government’s initiative to address the rising number of cancer cases in the country.
Health Secretary Robert F. Kennedy Jr. is a noted vaccine skeptic, and President Donald Trump has expressed concerns about ...
CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...
Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...
Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...